• 1
    NICE. Hypertension in pregnancy. 2010 []. Accessed 3 March 2013.
  • 2
    Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007;CD004659.
  • 3
    North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ 2011;342:d1875.
  • 4
    Smith GC. Researching new methods of screening for adverse pregnancy outcome: lessons from pre-eclampsia. PLoS Med 2012;9:e1001274.
  • 5
    Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, ter Riet G, Duley L, et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2008;12:iii–iv, 1270.
  • 6
    Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:9921005.
  • 7
    Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:67283.
  • 8
    Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011;31:6674.
  • 9
    Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009;53:8128.
  • 10
    Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008;199:266.e16.
  • 11
    Yu J, Shixia CZ, Wu Y Duan T. Inhibin A, activin A, placental growth factor and uterine artery Doppler pulsatility index in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2011;37:52833.
  • 12
    Akolekar R, de Cruz J, Foidart JM, Munaut C, Nicolaides KH. Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11–13 weeks of gestation in preeclampsia. Prenat Diagn 2010;30:1917.
  • 13
    Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, et al. Pregenesys pre-eclampsia markers consensus meeting: what do we require from markers, risk assessment and model systems to tailor preventive strategies? Placenta 2011;32(Suppl):S416.
  • 14
    Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, Varner MW, et al. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol 2012;119:123442.
  • 15
    Registry ANZCT. Screening for pregnancy endpoints: preeclampsia, growth restricted baby and spontaneous preterm birth. ACTRN12607000551493. 2007 []. Accessed 3 March 2013.
  • 16
    Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM. Case–control and two-gate designs in diagnostic accuracy studies. Clin Chem 2005;51:133541.
  • 17
    Brown MA, Hague WM, Higgins J, Lowe S, McCowan L, Oats J, et al. The detection, investigation and management of hypertension in pregnancy: full consensus statement. Aust N Z J Obstet Gynaecol 2000;40:13955.
  • 18
    Jones SR, Carley S, Harrison M. An introduction to power and sample size estimation. Emerg Med J 2003;20:4538.
  • 19
    R Core Team. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2012.
  • 20
    Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing the performance of scoring classifiers. R package version 1.0-4. 2009 []. Accessed 3 March 2013.
  • 21
    Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008;32:7329.
  • 22
    McCowan L, Stewart AW, Francis A, Gardosi J. A customised birthweight centile calculator developed for a New Zealand population. Aust N Z J Obstet Gynaecol 2004;44:42831.